Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return

Bulletin Express

May 06

Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.

The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.

No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.

The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1165791757"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1165791757\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1165791757?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 17:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165791757","market":"hk","top_or_hot":-1,"title":"Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.</p>\n<p>The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.</p>\n<p>No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBio-heart Confirms Stable Share Capital and Sufficient Public Float in April 2026 Monthly Return\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-06 17:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.</p>\n<p>The authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.</p>\n<p>No shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>The company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1165791757","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165791757","pubTimestamp":1778059409,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"Bio-heart确认2026年4月股本稳定及公众持股量充足月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (Bio-heart) reported no movements in share capital for the month ended 30 April 2026, according to its Monthly Return filed on 6 May 2026 with the Hong Kong Stock Exchange.\nThe authorised and issued H-share capital stood unchanged at 235.70 million shares with a par value of RMB 1 each. Unlisted foreign shares also remained steady at 7.71 million shares. Consequently, total authorised share capital stayed at RMB 243.42 million.\nNo shares were issued, repurchased, cancelled or held in treasury during the period. Bio-heart confirmed compliance with the Main Board’s minimum 25% public-float requirement.\nThe company reported no outstanding share options, warrants, convertibles or other equity-linked instruments. The filing was signed by Executive Director and Joint Company Secretary Wang Yuqing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}